{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T08:30:26Z","timestamp":1766219426819,"version":"3.48.0"},"reference-count":52,"publisher":"Wiley","issue":"18","license":[{"start":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T00:00:00Z","timestamp":1757894400000},"content-version":"vor","delay-in-days":14,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["19H03874"],"award-info":[{"award-number":["19H03874"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Backgrounds<\/jats:title>\n                    <jats:p>Pancreatic cancer is a highly aggressive disease with limited treatment options. The combination of tegafur, gimeracil, and oteracil (S\u20101) has emerged as a promising treatment approach in Japan. However, the economic implications of S\u20101 compared to other chemotherapy regimens have not been fully explored.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This cost\u2010effectiveness analysis study evaluated the economic position of S\u20101 relative to fluorouracil+leucovorin+irinotecan+oxaliplatin (FFX), gemcitabine+Nab\u2010paclitaxel (GnP), and gemcitabine (GEM) for the treatment of distant metastatic pancreatic cancer in Japan. Incremental cost\u2010effectiveness ratios were calculated using quality\u2010adjusted life years (QALYs) as the measure of effectiveness.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>S\u20101 demonstrated the lowest incremental cost\u2010effectiveness ratio compared to FFX, GnP, and GEM, indicating that it offers the most value for the cost. The total cost per QALY for S\u20101 was significantly lower than the other regimens. Additionally, S\u20101 was associated with favourable safety and convenience profiles.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The findings of this study suggest that S\u20101 is a cost\u2010effective and promising treatment option for distant metastatic pancreatic cancer in Japan. Its favourable economic profile, combined with its safety and convenience advantages, makes it a viable choice for patients and healthcare providers.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/cam4.71233","type":"journal-article","created":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T10:09:44Z","timestamp":1757930984000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cost\u2010Effectiveness Analysis of First\u2010Line Chemotherapy for Metastatic Pancreatic Cancer in Japan"],"prefix":"10.1002","volume":"14","author":[{"given":"Yuriko","family":"Sasahara","sequence":"first","affiliation":[{"name":"Department of Medical Oncology Yamagata Prefectural Central Hospital  Yamagata Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9191-3494","authenticated-orcid":false,"given":"Yuki","family":"Takumoto","sequence":"additional","affiliation":[{"name":"Department of Public Health and Epidemiology Meiji Pharmaceutical University  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsunori","family":"Murata","sequence":"additional","affiliation":[{"name":"CRECON Medical Assessment Inc  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manabu","family":"Akazawa","sequence":"additional","affiliation":[{"name":"Department of Public Health and Epidemiology Meiji Pharmaceutical University  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0383-4911","authenticated-orcid":false,"given":"Hiroto","family":"Narimatsu","sequence":"additional","affiliation":[{"name":"Cancer Prevention and Cancer Control Division Kanagawa Cancer Center Research Institute  Yokohama Kanagawa Japan"},{"name":"Graduate School of Health Innovation Kanagawa University of Human Services  Kawasaki Kanagawa Japan"},{"name":"Department of Genetic Medicine Kanagawa Cancer Center  Yokohama Kanagawa Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,9,15]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.29210"},{"key":"e_1_2_12_3_1","unstructured":"\u201cSEER Cancer Statistics Review (CSR) 1975\u20132015 \u201daccessed July 5 2024 https:\/\/seer.cancer.gov\/archive\/csr\/1975_2015\/index.html."},{"key":"e_1_2_12_4_1","unstructured":"Cancer Registry and Statistics Cancer Information Service National Cancer Center Japan \u201cCohort Life Table (In Japanese) \u201daccessed July 5 2024 https:\/\/ganjoho.jp\/reg_stat\/statistics\/data\/cohort\/excel\/cohort_table_2020.xls."},{"key":"e_1_2_12_5_1","unstructured":"Foundation for Promotion of Cancer Research \u201cCancer Statistics in Japan (2019) (In Japanese) \u201d(2019) accessed July 5 2024 https:\/\/ganjoho.jp\/data\/reg_stat\/statistics\/brochure\/2019\/cancer_statistics_2019_fig_E.pdf."},{"key":"e_1_2_12_6_1","unstructured":"Center for Cancer Control and Information Services National Cancer Center \u201cMonitoring of Cancer Incidence in Japan\u2010Survival 2006\u20132008 Report \u201d(2016) accessed July 5 2024 https:\/\/ganjoho.jp\/data\/en\/professional\/statistics\/files\/cancer_survival(1993\u20102008)E.xls."},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.2958\/suizo.23.105"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-023-02317-x"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1011923"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/cas.12501"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1304369"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.43.3680"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/jhbp.130"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.6.2403"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.6100"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.0373"},{"volume-title":"Cancer Drug Costs for a Month of Treatment at Initial Food and Drug Administration Approval","author":"PB B","key":"e_1_2_12_17_1"},{"key":"e_1_2_12_18_1","unstructured":"Ministry of Health L and Welfare \u201cHigh\u2010Cost Medical Expense Benefit (Eligibility Certificate for Ceiling\u2010Amount Application) or KOGAKU RYOYOHI SEIDO (GENDOGAKU TEKIYO NINTEISHO) (in Japanese) \u201daccessed July 6 2024 https:\/\/www.mhlw.go.jp\/stf\/seisakunitsuite\/bunya\/kenkou_iryou\/iryouhoken\/juuyou\/kougakuiryou\/index.html."},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JGO.19.00003"},{"key":"e_1_2_12_20_1","unstructured":"Center for Outcomes Research and Economic Evaluation for Health \u201cFull Scale Introduction of Cost\u2010Effectiveness Evaluations in Japan Overview \u201daccessed July 6 2024 https:\/\/c2h.niph.go.jp\/tools\/system\/overview_en.pdf."},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-199711020-00005"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-018-0684-8"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.3892\/mco.2017.1278"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vhri.2021.04.003"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2011.09.001"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.45515"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13561-022-00413-8"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.3389\/frhs.2024.1275496"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2021.10.008"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15020416"},{"key":"e_1_2_12_31_1","unstructured":"B. S.Woods E.Sideris S. J.Palmer N.Latimer andM.Soares \u201cNICE DSU Technical Support Document 19. Partitioned Survival Analysis for Decision Modelling in Health Care: A Critical Review \u201d(2017) accessed July 6 2024 https:\/\/www.sheffield.ac.uk\/sites\/default\/files\/2022\u201002\/TSD19\u2010Partitioned\u2010Survival\u2010Analysis\u2010final\u2010report.pdf."},{"key":"e_1_2_12_32_1","unstructured":"Center for Outcomes Research and Economic Evaluation for Health \u201cGuideline for Preparing Cost\u2010Effectiveness Evaluation to the Central Social Insurance Medical Council (Version 3.0) \u201daccessed July 6 2024 https:\/\/c2h.niph.go.jp\/tools\/guideline\/guideline_en.pdf."},{"key":"e_1_2_12_33_1","unstructured":"Statistics Bureau of Japan \u201cStatistic Japan Report Table\u00a02\u201320 (Data Is Available by 5\u2009Years of Age) \u201d(2018) accessed July 2024 https:\/\/www.stat.go.jp\/data\/nihon\/02.htm."},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp0911494"},{"key":"e_1_2_12_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(06)70910-X"},{"key":"e_1_2_12_36_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6603326"},{"key":"e_1_2_12_37_1","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-6-84"},{"key":"e_1_2_12_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10198-013-0503-2"},{"key":"e_1_2_12_39_1","doi-asserted-by":"publisher","DOI":"10.1002\/hec.1629"},{"key":"e_1_2_12_40_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02773"},{"key":"e_1_2_12_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02034-1"},{"key":"e_1_2_12_42_1","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyaa241"},{"key":"e_1_2_12_43_1","unstructured":"Ministry of Health Law \u201cVarious Information Medical Fee (in Japanese) \u201daccessed Feb 28 2024 https:\/\/shinryohoshu.mhlw.go.jp\/shinryohoshu\/searchMenu\/doSearchInputYp."},{"key":"e_1_2_12_44_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-018-3577-9"},{"key":"e_1_2_12_45_1","doi-asserted-by":"publisher","DOI":"10.3892\/mco.2023.2694"},{"issue":"5","key":"e_1_2_12_46_1","first-page":"209","article-title":"Evidence\u2010Baced Selection and Evaluation of Medicines Using Pharmacoeconomic Methods (In Japanese)","volume":"39","author":"Inoue T.","year":"2008","journal-title":"Journal of Clinical Pharmacology and Therapeutics"},{"key":"e_1_2_12_47_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.6777"},{"key":"e_1_2_12_48_1","doi-asserted-by":"publisher","DOI":"10.3999\/jscpt.41.265"},{"key":"e_1_2_12_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.09.2565"},{"key":"e_1_2_12_50_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.4_suppl.LBA661"},{"key":"e_1_2_12_51_1","doi-asserted-by":"publisher","DOI":"10.1080\/14728222.2021.1957462"},{"key":"e_1_2_12_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2011.06.014"},{"key":"e_1_2_12_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2011.06.013"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.71233","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T08:27:45Z","timestamp":1766219265000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.71233"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":52,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["10.1002\/cam4.71233"],"URL":"https:\/\/doi.org\/10.1002\/cam4.71233","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"type":"print","value":"2045-7634"},{"type":"electronic","value":"2045-7634"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"2024-11-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-29","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e71233"}}